Drug intelligence / Profile preview

Canavanine

Development stage
Preclinical
Modality
Small Molecules, Peptides
Administration
Oral
01

Overview

Canavanine is a non-proteinogenic amino acid found in certain leguminous plants. Structurally analogous to L-arginine, it differs by the replacement of a methylene group with an oxygen atom. Canavanine acts as a potent antimetabolite of arginine and is mistakenly incorporated into proteins in place of arginine by many organisms. This incorporation leads to the production of structurally aberrant and dysfunctional proteins that disrupt essential biochemical processes such as RNA and DNA metabolism and protein synthesis[3][6]. Canavanine also inhibits enzymes that utilize L-arginine—including nitric oxide synthase isoforms (notably inducible nitric oxide synthase/iNOS)[1][5]—and interferes with arginine uptake and metabolism[4][6]. In plants, it serves as a defensive allelochemical against herbivores due to its toxicity when consumed[3][8]. Experimentally, canavanine has demonstrated antitumor activity in preclinical models but has not been developed or approved for pharmaceutical use[7]. It is considered toxic at certain doses and may induce autoimmune-like symptoms in mammals.

Other names
L-canavanine(L)-canavanine2-amino-4-(guanidinooxy)butyric acidO-((aminoiminomethyl)amino)-L-homoserinecanavanin
02

Targets

aaRS (Aminoacyl-tRNA synthetase family)NOS1 (nNOS)NOS2 (Nitric Oxide Synthase 2)NOS3 (eNOS)

Beyond the preview

Go deeper on Canavanine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Canavanine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call